CRLX101: Phase I/II started

Cerulean said NIH’s NCI began an open-label, U.S. Phase I/II trial to evaluate IV CRLX101 in combination with oral Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). The Phase I portion will enroll up to 30 patients to identify the MTD or recommended Phase II dose. NCI is conducting the trial in collaboration with Cerulean and AZ. ...